Compugen Ltd.

CGEN

NASDAQ · Oncology Biotech

$1.96

At close - Nov 6, 4:00 PM EST - USD

Market Cap$185M

P/E5.3x

52W High$3.24

Volume183.99K

VCP Research Verdict2026Q2

Windfall Cash Burns Faster Than Deferred Revenue Grows

Compugen's Q4 2025 $67.3M revenue event and $56.8M net income produced an 84.4% net margin, but the company has reverted to a $1.3–2.6M quarterly revenue baseline with net losses of $7.0M–$7.7M in each of 2026's first two quarters, suggesting the windfall was non-recurring rather than a durable earnings inflection.

GrowthMixed

ProfitabilityNegative

ValuationReview

TechnicalsWeak

Explore valuation models

MARKET ACTION

CGEN price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

CGEN+26.45%

S&P 500 (^GSPC)+7.63%

1-Year Return

CGEN+19.51%

S&P 500 (^GSPC)+9.69%

3-Year Return

CGEN+170.64%

S&P 500 (^GSPC)+72.86%

5-Year Return

CGEN-70.70%

S&P 500 (^GSPC)+59.12%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E5Y High

5.3x

Forward P/E

N/A

EV/EBITDA100th %ile

2.8x

FCF YieldCash Flow

N/A

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

5.3x

4.0x

100th· High

EV/EBITDA

2.8x

1.8x

100th· High

Price/FCF

N/A

4.6x

N/A

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend

Revenue FY25

$73M+161.1% YoY

Net income FY25

$35M+348.4% YoY

Free cash flow FY25

$31M-36.7% YoY

Operating margin FY25

43.1%+96.5 pts YoY

ROIC (FY25)85.9%

Avg ROIC 5Y-1.9%

ROE (TTM)42.6%

Piotroski Score7 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate6/12 (50%)

Revenue Beat Rate9/12 (75%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest Aug 3, 2026	-$0.07+12.5% vs -$0.08	$3M+102.6% vs $1M
Q2 2026 May 18, 2026	-$0.08-14.3% vs -$0.07	$2M+38.5% vs $2M
Q2 2026 Mar 2, 2026	$0.60+957.1% vs -$0.07	$67M+3018.2% vs $2M
Q4 2025 Nov 10, 2025	-$0.07+22.2% vs -$0.09	$2M+61.9% vs $1M

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

4 Stories

PRNewsWire·4d ago

Compugen to Participate in November Investor Conferences

HOLON, Israel, Nov. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in the following upcoming investor conferences in November 2026: Stifel 2026 Healthcare Conference Date: Tuesday, November 10, 2026Location: New York, NYFormat: Fireside chat and 1x1 meetingsFireside chat time: 11:20 am ET 2026 Jefferies Global Healthcare Conference Date: Wednesday and Thursday, November 18-19, 2026Location: London, UKFormat: 1x1 meetings Please contact your Stifel or Jefferies representative for additional information or to schedule a meeting with Compugen.

Defense World·Oct 6, 2026

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets

Compugen (NASDAQ: CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Eran Ophir said COM701, a wholly owned anti-PVRIG antibody, is the company's most advanced internal program.

PRNewsWire·Oct 6, 2026

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference

HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C.

Seeking Alpha·Oct 5, 2026

Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript

Filtered for Compugen Ltd.More Headlines

Compare before deciding

Benchmark CGEN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Compugen Ltd. (CGEN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
CGENCompugen Ltd.Current	$1.96	$185.32M	5.27	161.14%	47.55%	42.57%	—
RXRXRecursion Pharmaceuticals, Inc.	$3.52	$1.85B	-4.02	26.92%	-697.13%	-47.85%	—
SDGRSchrödinger, Inc.	$29.82	$2.23B	-37.68	23.29%	-22.01%	-18.11%	—
ABSIAbsci Corporation	$10.17	$1.72B	-13.23	-38.24%	-7756.37%	-59.21%	—
INVAInnoviva, Inc.	$19.10	$1.41B	7.12	18.52%	43.79%	15.84%	—
NKTXNkarta, Inc.	$1.73	$123.77M	-1.00	—	—	-48.58%	—

Compare CGEN vs Peers

Compugen Ltd. (CGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RXRX

Most directly comparable listed peer for CGEN.

Scale Benchmark

vs TMO

Larger-name benchmark to compare CGEN against a more recognizable public peer.

Peer Set

Compare Top 5

vs RXRX, SDGR, ABSI, INVA

Get notified when CGEN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

CGEN Frequently Asked Questions

Compugen Ltd. (CGEN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Compugen Ltd.'s revenue?

Compugen Ltd. (CGEN) reported $74.0M in revenue over the trailing twelve months. Revenue was $72.8M in fiscal year 2025. That is 2148% more than the $3.2M of fiscal year 1999.

How fast is Compugen Ltd. growing?

Compugen Ltd. (CGEN) grew revenue by 234.2% over the trailing twelve months, compared with the twelve months before.

Is CGEN profitable?

Yes. Compugen Ltd. (CGEN) earned $35.2M in net income over the trailing twelve months (a 47.6% net margin).

Dividend & Returns

What is CGEN's return on equity?

Compugen Ltd. (CGEN) had a return on equity (ROE) of 42.6% over the trailing twelve months. That is well above the market's typical 10-15%.

What if you invested $1,000 in CGEN back in 1999?

Total return calculator · dividends reinvested · 27+ years of data

See returns →

Windfall Cash Burns Faster Than Deferred Revenue Grows

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Aug 3, 2026

-$0.07+12.5%

vs -$0.08

$3M+102.6%

vs $1M

Q2 2026

May 18, 2026

-$0.08-14.3%

vs -$0.07

$2M+38.5%

vs $2M

Q2 2026

Mar 2, 2026

$0.60+957.1%

vs -$0.07

$67M+3018.2%

vs $2M

Q4 2025

Nov 10, 2025

-$0.07+22.2%

vs -$0.09

$2M+61.9%

vs $1M

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

CGENCompugen Ltd.Current

$1.96

$185.32M

5.27

161.14%

47.55%

42.57%

—

RXRXRecursion Pharmaceuticals, Inc.

$3.52

$1.85B

-4.02

26.92%

-697.13%

-47.85%

—

SDGRSchrödinger, Inc.

$29.82

$2.23B

-37.68

23.29%

-22.01%

-18.11%

—

ABSIAbsci Corporation

$10.17

$1.72B

-13.23

-38.24%

-7756.37%

-59.21%

—

INVAInnoviva, Inc.

$19.10

$1.41B

7.12

18.52%

43.79%

15.84%

—

NKTXNkarta, Inc.

$1.73

$123.77M

-1.00

—

-48.58%

—